ALK Announces EURneffy Approval for Anaphylaxis Treatment
ALK, known for its innovative approaches in allergy treatments, has exciting news for those at risk of anaphylaxis. The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted approval for EURneffy 2 mg, marking a significant milestone as the first needle-free treatment for anaphylaxis in the UK.
Transformation in Allergy Emergency Care
EURneffy, the first adrenaline nasal spray approved for emergency allergic reactions, presents a promising alternative for those suffering from severe allergies. This novel solution aims to simplify how patients manage their allergies, enhancing the likelihood of positive outcomes when emergencies occur. Given that the UK is a key market for anaphylaxis treatment, this approval stands to significantly impact the lives of many individuals and families.
Design and Advantages of EURneffy
The unique design of EURneffy eliminates the need for needles, allowing easier administration of adrenaline when every second counts. This needle-free option not only increases confidence among users but also supports quicker response times in emergencies. With a robust shelf life of 30 months and better temperature stability compared to traditional auto-injectors, EURneffy is poised to become a game-changing treatment in emergency allergy care.
Significant Clinical Findings
In the development of EURneffy, over 700 participants were involved to ensure comprehensive assessment and effectiveness. The clinical studies yielded no serious adverse events, and the pharmacological data indicated that EURneffy performs on par with existing adrenaline auto-injectors. This finding is crucial as it reassures both medical professionals and patients of its safety and efficacy.
The Prevalence of Anaphylaxis
Anaphylaxis impacts a notable portion of the population, with studies indicating that up to eight people in every 100,000 in Europe are affected annually. Understanding the urgency behind creating simple solutions like EURneffy is critical, especially when many hesitated to use larger auto-injectors during emergencies.
Partnership with ARS Pharmaceuticals
EURneffy is a result of collaboration with ARS Pharmaceuticals, highlighting ALK's ongoing commitment to advancing treatment options. Their license agreement allows ALK exclusive global rights to distribute neffy, excluding several significant markets. This strategic partnership will likely strengthen the development and reach of innovative allergy treatments going forward.
Future Forward: The Impact on Financial Guidance
Despite the approval of EURneffy, ALK maintains its financial forecast for the upcoming years unchanged. This steady outlook reflects confidence in both current products and the new prospects brought to light by EURneffy, which holds promise for substantial growth in market share and patient support.
Contact Information and Company Background
ALK-Abelló A/S is a pioneering name in the field of allergy and allergic asthma treatments. With a team of approximately 2,800 employees globally, ALK is headquartered in Hørsholm, Denmark. The company not only manufactures but also markets allergy immunotherapy treatments, establishing itself as a trusted partner for allergy care.
For more information, the Investor Relations contact is Per Plotnikof at tel. +45 4574 7527, mobile +45 2261 2525. Media inquiries can be directed to Maiken Riise Andersen at tel. +45 5054 1434.
Frequently Asked Questions
What is EURneffy?
EURneffy is a needle-free adrenaline nasal spray approved for the emergency treatment of anaphylaxis in adults and children.
How does EURneffy compare to traditional auto-injectors?
EURneffy offers a more user-friendly, needle-free design with an increased shelf life and better temperature stability compared to standard adrenaline auto-injectors.
Who can use EURneffy?
It is designed for users ?30 kg, allowing both adults and adolescents to manage severe allergic reactions effectively.
What were the clinical study outcomes for EURneffy?
Clinical studies involving over 700 participants showed no serious adverse events, with results comparable to traditional auto-injectors.
What is the significance of the MHRA's approval?
The approval signifies a crucial advancement in emergency allergy care, providing a novel treatment option that could save lives and improve the quality of care for those at risk of anaphylaxis.
